Is natalizumab effective in the treatment of Crohn disease and how is it administered?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

Natalizumab is a humanized monoclonal antibody that prevents the accumulation of lymphocytes in the diseased bowel by binding α4β7 integrin (gut specific). It also binds to α4β1 integrin (CNS specific). Clinical data indicate that this drug is effective in inducing clinical response and remission of active moderate to severe Crohn disease. It is administered in a single 300-mg dose every 4 weeks up to 12 weeks, at which time it may be stopped if it is not effective.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!